Monday, July 28, 2008

Fwd: Breast cancer in young families: a qualitative interview study of fathers and their role and communication with their children following the diagnosis of maternal breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Breast cancer in young families: a qualitative interview study of fathers and their role and communication with their children following the diagnosis of maternal breast cancer.
To: mesothelioma77@gmail.com


[1]Psychooncology. 2008 Jul 11;
Forrest G, Plumb C, Ziebland S, Stein A

Objective: To explore father-child communication following the diagnosis of maternal breast cancer, examine disparities in their understandings of the impact of the illness, and identify gaps in their need for support and information.Methods: The design is the qualitative interview study with thematic analysis. The interviews were home-based with fathers and children in Oxfordshire, UK. The participants were 26 fathers whose partners had early breast cancer and 31 of their children aged between 6 and 18 years.Results: Fathers described graphically their reaction to news of their partner's breast cancer and their attempts to provide support for their partners and maintain normal family life for their children. Fathers were keen to reassure and protect children but often said that they lacked sufficient information about breast cancer-especially side effects of treatments. Fathers sometimes did not recognise the extent of their children's distress and some interpreted their children's reactions as 'bad behaviour' or 'rudeness'. Children were often acutely aware of the father's emotional state, and expressed a wish to protect him. Some fathers would have liked an opportunity to talk to a clinician directly about the children but did not want to claim clinical time for themselves or their children.Conclusion: This study suggests that clinicians could improve their care of breast cancer patients by being more family-centred. Fathers routinely need more information and preparation about the likely impact of the illness and its treatment (especially side effects) on the mother, and how children of different ages may react to the emotional strain. Clinicians need to be prepared to offer to talk to teenagers. Copyright (c) 2008 John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18618898
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Abstracting height and weight from medical records, and breast cancer pathologic factors.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Abstracting height and weight from medical records, and breast cancer pathologic factors.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Jul 10;
McEligot AJ, Im T, Dillman RO, West JG, Salem R, Haque R, Anton-Culver H

Cancer registries routinely collect data on clinicopathologic factors, but rarely abstract anthropometric variables. We conducted a chart review study, examining the feasibility of abstracting weight, height, alcohol use, and smoking from medical records in women (n = 1,974) diagnosed with invasive breast cancer, and investigated the association between the abstracted variables with clinicopathologic features. Qualitative data were reviewed and categorized. Frequencies of the abstracted data, and demographic and clinicopathologic variables were calculated. Logistic regression models measured the relationship between the outcome variables, tumor size, stage of disease, and estrogen/progesterone (ER/PR) status with the abstracted variables. Data on current alcohol-use/no-use, current-smoker/non-smoker, and height/weight data were obtained on 96%, 97%, and 88-89% of the participants, respectively. The multivariate analysis showed that overweight (>/=25 kg/m(2)) women had significantly larger (>/=2 cm) tumor size compared with normal weight for both women /=50 years at diagnosis (OR = 1.58; 95% CI = 1.19-2.09; p

___
Source: http://www.hubmed.org/display.cgi?uids=18618281
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 http://www.jgvfinance.com/
 

 

Fwd: Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jul 10;
Auer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, Marth C, Müller-Holzner E, Daxenbichler G, Zeimet AG

This study analyzes the relationship between coxsackie-adenovirus receptor (CAR) expression (transmembrane and soluble isoforms) and hormone sensitivity in 95 breast cancers. Furthermore, prognostic significance of the expression of the various CAR isoforms was investigated. In addition, inducibility of CAR expression by estradiol and tamoxifen was assessed in various breast cancer cell lines. Expression of transmembrane CAR (hCAR) highly correlated with estrogen receptivity, but was independent of the expression of progesterone receptor (PR). Furthermore, hCAR expression was significantly higher in tumors with low-grade malignancy. However, no relationship between hCAR expression and tumor size, lymph node status, or survival was revealed. In the hormone receptor-positive breast cancer cell line T47-D expression of hCAR and its soluble isoforms was increased by treatment with estradiol and tamoxifen. In contrast, no induction of either CAR isoform was achieved in receptor-negative cell lines. Furthermore, enhancement of hCAR expression was significantly greater when cells were treated with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) than when treated with estradiol or tamoxifen. Moreover, sensitivity to TSA induction of hCAR was considerably greater in receptor-positive than in receptor-negative cell lines. No additive effect on CAR expression was found when TSA was combined with either estradiol or tamoxifen. In conclusion, the so far undescribed association between estrogen receptivity and the expression of hCAR in breast cancer seems to not only reflect a phenotype of low malignancy, but expression of hCAR may also be directly influenced by ER-specific ligands.



___
Source: http://www.hubmed.org/display.cgi?uids=18618240
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 http://www.jgvfinance.com/
 

 

Fwd: Combined Axillary Reverse Mapping (ARM) Technique for Breast Cancer Patients Requiring Axillary Dissection.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Combined Axillary Reverse Mapping (ARM) Technique for Breast Cancer Patients Requiring Axillary Dissection.
To: mesothelioma77@gmail.com


[1]Ann Surg Oncol. 2008 Jul 11;
Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, Lecuru F

BACKGROUND: The objective of axillary reverse mapping (ARM) is to preserve the main lymphatic chain-with both the nodes and the ducts-in relation to lymphatic arm drainage (LAD) during an axillary dissection (AD). METHODS: From July 2006 to March 2008, 23 patients with stage II or III breast carcinoma requiring an AD underwent an ARM procedure. Identification of the ARM nodes relied on an isotope injection into the web space of the ipsilateral hand. During AD, the radioactive ARM node was localized above the second intercostal brachial nerve, and blue dye was directly injected inside the node to visualize the efferent ducts, constituting the lymphatic ARM chain. The blue and radioactive nodes constituted the ARM sampling, while other nodes were considered part of the AD. RESULTS: Metastatic lymph node involvement was identified in the AD in 20 of 23 patients, with an average of 4.4 (1-11) nodes involved and an average of 10.7 (7-20) lymph nodes removed. The ARM sampling was performed in 21 of 23 patients (91%), with an average of 1.6 ARM nodes removed. In 18 of these 21 patients (86%), the nodes relating to ARM sampling had no metastatic involvement. There were 3 patients (14%) who demonstrated metastatic involvement of the ARM sampling, and all had pN3a (N+ > 9) involvement of the axilla. CONCLUSION: This technique of combined isotopic and blue dye ARM and findings must now be validated. A multicentric study is planned to confirm this data.



___
Source: http://www.hubmed.org/display.cgi?uids=18618185
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 http://www.jgvfinance.com/
 

 

Fwd: Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 14, 2008 at 4:55 AM
Subject: Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer.
To: mesothelioma77@gmail.com


[1]Jpn J Clin Oncol. 2008 Jul 10;
Ono M, Watanabe T, Shimizu C, Hiramoto N, Goto Y, Yonemori K, Kouno T, Ando M, Tamura K, Katsumata N, Fujiwara Y

We report a patient with therapy-related acute promyelocytic leukemia (APL) that may have been caused by regional radiation or hormonal therapy after surgery. A 36-year-old Japanese woman developed right breast cancer and underwent breast-conserving surgery and regional radiation to the right breast without adjuvant systemic therapy because she wished to preserve her fertility. Two years later, she developed multiple bone metastases of breast cancer and received hormonal therapy. During the second line hormonal therapy, she developed APL and received induction and consolidation chemotherapy with all-trans retinoic acid (ATRA) and a combination of anthracycline and cytarabine. After she achieved a complete remission (CR) of the APL, her bone metastases of breast cancer progressed. She received weekly paclitaxel treatments and her bone marrow function recovered. However, 9 months later, her APL relapsed; she achieved a second CR after undergoing ATRA therapy again. This patient is thought to be a rare case of secondary leukemia, since the leukemia might have been caused by hormonal therapy and regional radiation without chemotherapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18617535
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: For cancer data worker, the disease has become personal (The Sacramento Bee)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: For cancer data worker, the disease has become personal (The Sacramento Bee)
To: mesothelioma77@gmail.com


For seven years, cancer was a matrix of numbers on Della Blankenship's computer screen. Della Blankenship, who works for the California Cancer Registry, is herself trying to beat a cancer. Della Blankenship, who is being treated for Hodgkin's lymphoma, relaxes with Suki on Thursday in their Land Park apartment. "Every moment that I am alive is the best moment of my life," says the ...

Sat, 19 Jul 2008 07:19:35 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11gui4pb0/*http%3A//www.sacbee.com/101/story/1094046.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Lifewatch: Lung cancer development (WECT 6 Wilmington)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Lifewatch: Lung cancer development (WECT 6 Wilmington)
To: mesothelioma77@gmail.com


About 200,000 people are diagnosed with new cases of lung cancer each year. Until now, surgery required long and trying hospital stays.  A new development is making recovery faster and less painful.

Wed, 16 Jul 2008 15:28:45 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11ionl980/*http%3A//www.wect.com/global/story.asp?s=8684311
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
To: mesothelioma77@gmail.com


[1]Int J Med Sci. 2008; 5(4): 197-202
Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Dib AB, Bignon YJ

Breast cancer rates and median age of onset differ between Western Europe and North Africa. In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among Africans. To help determine the contribution of BRCA1 mutations to breast cancer in a North African population, we analysed genomic DNA from breast cancer cases ascertained in Algiers.Both familial cases (at least three breast cancers in the same familial branch, or two with one bilateral or diagnosed before age 40) and sporadic cases less than 38 years of age were studied. Complete sequencing plus quantitative analysis of the BRCA1 gene was performed. 9.8 % (5/51) of early-onset sporadic and 36.4 % (4/11) of familial cases were found to be associated with BRCA1 mutations. This is in contrast 10.3 % of French HBOC families exhibiting a BRCA1 mutation. One mutation, c.798_799delTT, was observed in two Algerian families and in two families from Tunisia, suggesting a North African founder allele. Algerian non-BRCA1 tumors were of significantly higher grade than French non-BRCA tumors, and the age at diagnosis for Algerian familial cases was much younger than that for French non-BRCA familial cases. In conclusion, we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern African population.



___
Source: http://www.hubmed.org/display.cgi?uids=18645608
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc